Seven Years of Clinical Experience Outcome Review on Radium 223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)

被引：0
|
作者：
Cantinho-Lopes, M. [1 ]
Pena, H. [1 ]
Filipe, P. [2 ]
Mansinho, A. [2 ]
Fernandes, I. [2 ]
Costa, L. [2 ]
机构：
[1] Fac Med Lisbon, Inst Med Nucl, Lisbon, Portugal
[2] CHULN, S Oncol, Lisbon, Portugal
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2022年 / 49卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-225
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [31] Metastatic Castrate-Resistant Prostate Cancer Practical Review
    Moeller, Abby
    Cookson, Michael
    Patel, Sanjay G.
    PHYSICIAN ASSISTANT CLINICS, 2018, 3 (01) : 11 - +
  • [32] Radium-223 therapy in symptomatic metastatic castrate resistant prostate cancer (mCRPC) - sequential use post-abiraterone/prednisolone
    Jiang, Xue Yan
    Atkinson, Sarah
    Cumming, Sam
    Burns, Alexander
    Pearson, Rachel
    Frew, John
    McMenemin, Rhona
    Azzabi, Ashraf
    Leaning, Darren
    Pedley, Ian
    CLINICAL ONCOLOGY, 2019, 31 : E10 - E11
  • [33] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [35] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [36] Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience
    Jimenez-Romero, Miguel E.
    Canelon-Castillo, Elba Y.
    Diez-Farto, Sara
    Santotoribio, Jose Diego
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 (05) : 567 - 573
  • [37] Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer
    McNamara, Megan Ann
    Oyekunle, Taofik
    Chin, Bennett B.
    Oldan, Jorge
    Anand, Aseem
    Ritz, Michala
    Shantzer, Lindsey
    Anand, Monika
    Armstrong, Andrew J.
    George, Daniel J.
    PROSTATE, 2019, 79 (10): : 1106 - 1116
  • [38] Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects
    van der Doelen, Maarten J.
    Velho, Pedro Isaacsson
    Slootbeek, Peter H. J.
    Naga, Samhita Pamidimarri
    Bormann, Maren
    van Helvert, Sjoerd
    Kroeze, Leonie I.
    van Oort, Inge M.
    Gerritsen, Winald R.
    Antonarakis, Emmanuel S.
    Mehra, Niven
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)
    Marshall, Catherine Handy
    Park, Jong Chul
    DeWeese, Theodore L.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin M.
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
    Iacovelli, R.
    Ciccarese, C.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1192 - 1193
12345